0001479290-20-000071.txt : 20200515 0001479290-20-000071.hdr.sgml : 20200515 20200515184525 ACCESSION NUMBER: 0001479290-20-000071 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200514 FILED AS OF DATE: 20200515 DATE AS OF CHANGE: 20200515 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Beraud Jill CENTRAL INDEX KEY: 0001520061 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 20887298 MAIL ADDRESS: STREET 1: C/O LEVI STRAUSS & CO. STREET 2: 1155 BATTERY STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 4 1 wf-form4_158958268428146.xml FORM 4 X0306 4 2020-05-14 0 0001479290 Revance Therapeutics, Inc. RVNC 0001520061 Beraud Jill C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BLVD NEWARK CA 94560 1 0 0 0 Common Stock 2020-05-14 4 A 0 6000 0 A 15000 D Stock Option (Right to buy) 19.4 2020-05-14 4 A 0 12000 0 A 2030-05-13 Common Stock 12000.0 12000 D Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Ms. Beraud's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Ms. Beraud's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. /s/ Gordon Ho, Attorney-in-Fact 2020-05-15